Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Australian Household Spending Dips in December as RBA Tightens Policy 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
